The investigation of hyaluronic acid and hyaluronidase ‐1 levels as tumor marker in larynx cancer
Hakkı Caner İnan Murat Yener Nur Buyru Asuman Çelebi Mehmet Yilmaz Nil Çomunoğlu
First published: 17 June 2019 https://doi.org/10.1111/coa.13390
Corresponding author:Hakkı Caner İNAN, MD,Cerrahpasa Medical Faculty, Department of Otorhinolaryngology, Istanbul University, Kocamustafapasa, 34098 Istanbul, Turkey. Phone number:+905442653430. hakkicanerinan@gmail.com
This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/coa.13390
ePDFPDFTOOLS SHARE
Abstract
Objective
The purpose of this study was to investigate the hyaluronic acid (HA) and Hyaluronidase‐1 (HYAL‐1) levels in laryngeal cancer patients. Study design: Prospective, controlled clinical trial.
Setting
University Medical Center. Participants: 50 laryngeal squamous cell carcinoma patients and 50 volunteers who gave saliva samples investigated prospectively between 2016‐2017.
Methods
Hyaluronidase‐1 expression was measured by RT‐PCR in normal and tumor tissue samples; hyaluronic acid values of saliva and tumor tissues were measured by ELISA method.
Results
HYAL‐1 expression increased 2.5‐fold in tumor tissues compared to normal tissues and the difference was statistically significant (p <0.001).Mean saliva HA levels were 103.93±69.04 ng/ml and 177.29±98.44 ng/ml in the patients and controls’ saliva specimens, respectively. The difference was not statistically significant (p= 0.657)HA levels were higher in tumor tissue samples than saliva samples, but there was not statistically significant difference between saliva and tumor tissue HA levels.
Conclusion
HYAL‐1 expression in laryngeal squamous cell carcinomas is elevated compared to normal tissues of same patients. Targetting this gene ant HA catabolism products may use treatment of larynx cancer in the future.
Hakkı Caner İnan Murat Yener Nur Buyru Asuman Çelebi Mehmet Yilmaz Nil Çomunoğlu
First published: 17 June 2019 https://doi.org/10.1111/coa.13390
Corresponding author:Hakkı Caner İNAN, MD,Cerrahpasa Medical Faculty, Department of Otorhinolaryngology, Istanbul University, Kocamustafapasa, 34098 Istanbul, Turkey. Phone number:+905442653430. hakkicanerinan@gmail.com
This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/coa.13390
ePDFPDFTOOLS SHARE
Abstract
Objective
The purpose of this study was to investigate the hyaluronic acid (HA) and Hyaluronidase‐1 (HYAL‐1) levels in laryngeal cancer patients. Study design: Prospective, controlled clinical trial.
Setting
University Medical Center. Participants: 50 laryngeal squamous cell carcinoma patients and 50 volunteers who gave saliva samples investigated prospectively between 2016‐2017.
Methods
Hyaluronidase‐1 expression was measured by RT‐PCR in normal and tumor tissue samples; hyaluronic acid values of saliva and tumor tissues were measured by ELISA method.
Results
HYAL‐1 expression increased 2.5‐fold in tumor tissues compared to normal tissues and the difference was statistically significant (p <0.001).Mean saliva HA levels were 103.93±69.04 ng/ml and 177.29±98.44 ng/ml in the patients and controls’ saliva specimens, respectively. The difference was not statistically significant (p= 0.657)HA levels were higher in tumor tissue samples than saliva samples, but there was not statistically significant difference between saliva and tumor tissue HA levels.
Conclusion
HYAL‐1 expression in laryngeal squamous cell carcinomas is elevated compared to normal tissues of same patients. Targetting this gene ant HA catabolism products may use treatment of larynx cancer in the future.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου